Nerviano Medical Sciences S.r.l.

Juergen Moll

Tiziano Bandiera

Daniele Fancelli

Italo Beria

Dario Ballinari

Maurizio Pulici

Enrico Pesenti

Francesca Quartieri

Antonella Isacchi

Barbara Valsasina

Rosita Lupi

Michele Modugno

Antonella Ciavolella

Valter Domenico Croci

Luisa Rusconi

Chiara Soncini

Maurizio D'Incalci

The present invention provides a combination comprising (a) a compound of formula (I) and (b) one or more antineoplastic agents selected from the group consisting of an antimetabolite agent, analkylating or alkylating-like agent, an intercalating agent, a topoisomerase I or II inhibitor, an antimitotic agent, a kinase inhibitor, a proteasome inhibitor and an antibody inhibiting a growth factor or its receptor, wherein active ingredients of the combination are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate or solvate thereof, useful in the treatment of tumors. 

Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent

The invention provides low molecular weight compounds, namely tetrahydropyrrolo[3,4-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.

Use of a kinase inhibitor for the treatment of particular resistant tumors

Growing community of inventors

Appiano Gentile, Italy

Juergen Moll